Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 19.31
-0.23 (-1.18%)
At close: Feb 13, 2026
Sansure Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,635 | 1,424 | 991.1 | 6,304 | 4,342 | 4,598 |
Other Revenue | 34.14 | 34.14 | 16.02 | 146.58 | 172.86 | 164.99 |
| 1,670 | 1,458 | 1,007 | 6,450 | 4,515 | 4,763 | |
Revenue Growth (YoY) | 18.65% | 44.78% | -84.39% | 42.88% | -5.22% | 1203.53% |
Cost of Revenue | 383.61 | 279.71 | 280.96 | 2,912 | 1,283 | 971.99 |
Gross Profit | 1,286 | 1,178 | 726.15 | 3,538 | 3,232 | 3,791 |
Selling, General & Admin | 824 | 749.79 | 547.37 | 939.48 | 488.21 | 603.01 |
Research & Development | 265.56 | 276.64 | 194.81 | 331.2 | 186.84 | 82.62 |
Other Operating Expenses | 67.2 | 10.96 | 0.1 | 27.31 | 12.48 | 11.71 |
Operating Expenses | 1,170 | 1,051 | 747.23 | 1,344 | 706.01 | 721.28 |
Operating Income | 115.53 | 127.26 | -21.08 | 2,194 | 2,526 | 3,070 |
Interest Expense | -19.16 | -18.4 | -2.41 | -2.09 | -0.83 | -0.51 |
Interest & Investment Income | 85.36 | 97.53 | 308.41 | 48.35 | 32.53 | 33.06 |
Currency Exchange Gain (Loss) | 6.85 | 6.85 | 4.31 | 5.04 | -42.25 | -43.71 |
Other Non Operating Income (Expenses) | 8.65 | -1.77 | -9.15 | -7.94 | -1.61 | -0.7 |
EBT Excluding Unusual Items | 197.23 | 211.46 | 280.08 | 2,237 | 2,513 | 3,058 |
Impairment of Goodwill | - | - | - | -1.44 | - | - |
Gain (Loss) on Sale of Investments | 9.97 | -20.44 | 61.84 | 79.24 | 81.01 | 6.23 |
Gain (Loss) on Sale of Assets | -6.66 | -4.21 | -7.21 | -5.47 | 0.41 | 0.97 |
Asset Writedown | -17.87 | -1.25 | - | -15.1 | - | - |
Other Unusual Items | 57.51 | 75.04 | 75.76 | 21.3 | 21.37 | 5.13 |
Pretax Income | 240.18 | 260.61 | 410.48 | 2,316 | 2,616 | 3,070 |
Income Tax Expense | 15.01 | 34.34 | 62.31 | 379.21 | 373.68 | 453.56 |
Earnings From Continuing Operations | 225.17 | 226.27 | 348.17 | 1,937 | 2,243 | 2,617 |
Minority Interest in Earnings | 46.32 | 49.32 | 15.55 | 0.09 | 0.17 | - |
Net Income | 271.49 | 275.6 | 363.72 | 1,937 | 2,243 | 2,617 |
Net Income to Common | 271.49 | 275.6 | 363.72 | 1,937 | 2,243 | 2,617 |
Net Income Growth | 4.65% | -24.23% | -81.22% | -13.64% | -14.29% | 6527.90% |
Shares Outstanding (Basic) | 590 | 586 | 587 | 585 | 589 | 552 |
Shares Outstanding (Diluted) | 674 | 586 | 587 | 585 | 589 | 552 |
Shares Change (YoY) | 14.18% | -0.05% | 0.26% | -0.59% | 6.55% | 3.97% |
EPS (Basic) | 0.46 | 0.47 | 0.62 | 3.31 | 3.81 | 4.74 |
EPS (Diluted) | 0.40 | 0.47 | 0.62 | 3.31 | 3.81 | 4.74 |
EPS Growth | -8.34% | -24.19% | -81.27% | -13.12% | -19.56% | 6274.83% |
Free Cash Flow | -214.9 | -146.66 | -347.81 | 2,000 | 1,504 | 2,534 |
Free Cash Flow Per Share | -0.32 | -0.25 | -0.59 | 3.42 | 2.56 | 4.59 |
Dividend Per Share | 0.537 | 0.525 | 0.462 | 1.298 | 0.760 | 0.760 |
Dividend Growth | 19.33% | 13.59% | -64.39% | 70.77% | - | - |
Gross Margin | 77.02% | 80.82% | 72.10% | 54.85% | 71.58% | 79.59% |
Operating Margin | 6.92% | 8.73% | -2.09% | 34.01% | 55.94% | 64.45% |
Profit Margin | 16.26% | 18.90% | 36.12% | 30.03% | 49.68% | 54.94% |
Free Cash Flow Margin | -12.87% | -10.06% | -34.53% | 31.01% | 33.32% | 53.19% |
EBITDA | 285.98 | 267.89 | 79.8 | 2,269 | 2,571 | 3,096 |
EBITDA Margin | 17.13% | 18.37% | 7.92% | 35.18% | 56.96% | 65.01% |
D&A For EBITDA | 170.45 | 140.63 | 100.88 | 75.47 | 45.89 | 26.68 |
EBIT | 115.53 | 127.26 | -21.08 | 2,194 | 2,526 | 3,070 |
EBIT Margin | 6.92% | 8.73% | -2.09% | 34.01% | 55.94% | 64.45% |
Effective Tax Rate | 6.25% | 13.18% | 15.18% | 16.37% | 14.28% | 14.77% |
Revenue as Reported | 1,670 | 1,458 | 1,007 | 6,450 | 4,515 | 4,763 |
Advertising Expenses | - | 68.07 | 26.28 | 36.36 | 32.38 | 27.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.